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| INTRODUC TI ON
Atrial fibrillation (AF) is the most common cardiac arrhythmia in adults, coexisting with vascular disease in about 30% of patients.
Over 80% of patients with AF have ≥1 stroke risk factor(s), thus requiring stroke prevention therapy, most commonly using oral anticoagulants (OACs). 1 Given that the estimated global prevalence of AF is 1% to 3% and around 20% of patients with AF would need a percutaneous coronary intervention (PCI), about 1 to 3 million Europeans with AF taking OACs may require PCI. [2] [3] [4] [5] Patients with AF and acute coronary syndrome (ACS) (ie, unstable angina, non-ST-segment elevation myocardial infarction [MI] or ST-segment elevation MI) have particularly high risk of recurrent coronary events (ie, MI or stent thrombosis), stroke, and cardiovascular mortality. 6 Preventing stroke, recurrent cardiac ischemia, and stent thrombosis using a combined antithrombotic therapy needs to be balanced against the risk of major bleeding (including intracranial hemorrhage ICH; Figure 1 ). 1, 7 The use of dual antiplatelet therapy (DAPT) alone would not sufficiently protect patients against stroke, whereas OAC monotherapy, either a direct oral anticoagulant (DOAC) or vitamin K antagonist (VKA), would not protect patients against new coronary events. 8, 9 Triple therapy (TT) using DAPT in combination with an OAC effectively prevents vascular ischemic events but is associated with considerably increased risk of bleeding. 10 
| OVERVIEW OF PUBLISHED DATA
Various studies have addressed the challenging management of patients with AF and ACS. Observational studies have shown that in AF patients after MI/PCI, dual antithrombotic therapy (clopidogrel and OAC) was equal to or better than TT in terms of benefit (MI or coronary death, fatal or nonfatal ischemic stroke, and all-cause mortality) and safety outcomes (fatal or nonfatal bleeding). 11 In the Management of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry, 12 TT, DAPT, and dual antithrombotic therapy (VKA with clopidogrel) had similar 1-year efficacy (stroke/transient ischemic events, peripheral embolism, MI, revascularization, definite/probable stent thrombosis) and safety (minor and major bleedings), but the study was limited by a low rate of adverse events and relatively small size of the group taking VKA with clopidogrel.
In the warfarin era, the What Is the Optimal Antiplatelet and Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary Stenting (WOEST) trial assessed the use of antiplatelet therapy in patients on a VKA. 13 The use of dual antithrombotic therapy (clopidogrel and a VKA) was compared to triple therapy (VKA and clopidogrel plus aspirin). Dual antithrombotic therapy was associated with significantly lower risk of Thrombolysis in Myocardial Infarction (TIMI) minor and major bleeding in comparison to TT (of note, there was no significant difference in major bleeds). However, the trial was small; not all patients were taking OACs for AF-related stroke prevention (69% of patients had AF) and 25% to 30% of participants had an ACS; radial access was chosen in only 25% to 27% of patients; and TT was continued for 12 months. Notably, the WOEST trial also showed that patients taking TT had a higher risk of mortality compared with those on dual antithrombotic therapy (ie, clopidogrel and a VKA).
In the contemporary era of DOACs, post hoc analyses of the landmark DOACs trials for stroke prevention in AF showed consistent efficacy and safety of the respective DOAC versus warfarin irrespective of the concomitant aspirin use or nonuse. [14] [15] [16] [17] Although patients concomitantly using an antiplatelet drug (mostly aspirin) and OAC (either a DOAC or warfarin) were at higher risk of both ischemic and bleeding events compared with those on OAC monotherapy, the rates of hemorrhagic stroke or ICH were consistently lower with DOACs in comparison to warfarin. [14] [15] [16] [17] Contemporary observational studies consistently reported findings similar to those substudies. The Danish nationwide registry-based study, for example, reported that among patients with AF and MI and/ or PCI, those taking a DOAC plus DAPT had a significantly lower risk of bleeding than patients taking a VKA plus DAPT, with no significant differences in all-cause mortality, ischemic stroke, or MI between the 2 treatment regimens. 18 The study was limited by lack of significant pa- Four recent open-label, randomized, controlled clinical trials investigated the use of DOACs in patients with AF with a recent ACS and/or undergoing a PCI [19] [20] [21] [22] see Table 1 . The PIONEER AF-PCI (an open-label, randomized, controlled, multicenter study exploring 2 treatment strategies of rivaroxaban and dose-adjusted oral VKA treatment strategy in subjects with AF undergoing PCI) 19 was an exploratory study comparing bleeding rates across 3 strategies (low-dose rivaroxaban Both the PIONEER AF-PCI and RE-DUAL PCI trial clearly showed that dual therapy including the respective DOAC plus a P2Y 12 inhibitor (mostly clopidogrel) was associated with significantly less major bleeding in comparison to TT with VKA plus dual antiplatelet therapy. However, these trials could not distinguish whether the bleeding risk reduction was driven by the use of a DOAC or nonuse of aspirin, or both.
Apixaban was tested in an open-label, 2 × 2 factorial, randomized controlled trial evaluating the safety of apixaban versus VKA and aspirin versus placebo in patients with AF and ACS and/or PCI (the AUGUSTUS trial). 21 Patients with AF and an ACS and/or PCI within the preceding 14 days were randomized to apixaban 5 mg twice daily (or apixaban 2.5 mg twice daily in patients fulfilling dose reduction criteria) versus VKA and to aspirin versus aspirin-placebo. The primary outcome was major bleeding defined by TA B L E 1 Randomized clinical trials of combined antithrombotic therapies in patients with AF with ACS or PCI/Stenting PIONEER-AF PCI 23 RE-DUAL PCI 20 
ENTRUST-AF PCI 22 AUGUSTUS 24
Objective Rivaroxaban + P2Y 12 with significantly lower incidence of bleeding when compared to regimen with VKA, aspirin, or both. Apixaban without aspirin was also correlated with significantly lower incidence of hospitalizations than VKA, aspirin, or both. There were no significant differences in ischemic events, although the rates of stent thrombosis and cardiovascular events were numerically higher in the placebo-treated patients compared to those on aspirin, while the rate of stroke was lower in patients on apixaban than in those on VKA. 24 One of the major study limitations is the poor quality of anticoagulation with VKA (time in therapeutic range [TTR] in patients on VKA was lower than in previous randomized trials).
In the Safety and Efficacy of an Edoxaban-Based Antithrombotic 12 and aspirin TT regimens), 25 DOAC-based dual treatments were associated with fewer TIMI major bleedings and less ICH compared with VKA with DAPT, and there was no statistically significant difference in the rates of major adverse cardiac events, all-cause death, and cardiovascular mortality among the 4 treatment regimens. No statistically significant differences were revealed with respect to stroke, MI, and stent thrombosis among the treatment regimens (see Table 2 ).
In another meta-analysis, 26 data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials were evaluated. The use of DOACs was associated with significantly lower rates of bleeding and similar rates of ischemic events (stroke, MI, and stent thrombosis) and allcause death/cardiovascular mortality than VKA-based treatments ( Table 3 ). Dual antithrombotic therapy was associated with a significantly lower incidence of bleeding; similar rates of stroke, MI, and all-cause/cardiovascular death; and a significantly greater risk of stent thrombosis when compared with TT (Table 3) .
Overall, available data support the use of full-dose DOAC (dabigatran 150 mg twice daily or apixaban 5 mg twice daily) or rivarox- 
| TT IN PATIENTS WITH AF AND ACS FROM DISCHARGE TO 12 MONTHS AFTER ACS
Owing to increased stroke risk in patients with ACS and AF, such patients should be considered for concomitant OAC use. 27 There is no single strategy of TT use that would be suitable for all patients with AF and ACS. The composition and duration of TT should be individualized based on the estimated bleeding and cardioembolic and atherothrombotic risks in each patient. [28] [29] [30] [31] [32] should be identified and actively managed. 28, 33, 34 Of note, the use of a formal bleeding risk score has been shown to be superior to relying only on an approach based on modifiable bleeding risk factors. 35 
| BLEEDING PREVENTION AND BLEEDING REDUCTION STRATEGIES
TT is associated with increased rates of major bleeding ranging from 5% to 15% at 1 year. [36] [37] [38] [39] [40] Unfortunately, major bleeding may result in a 2-to 8-fold increase in the risk of mortality and nonfatal cardiovascular events. [41] [42] [43] [44] [45] The risk of bleeding varies with different antithrombotic treatment regimens. The risk of bleeding with aspirin together with clopidogrel is higher during the early months after initiation.
Bleeding on warfarin is also highest in the early period after the drug initiation (initial 3 months). 46 Clinical risk scores may facilitate decision making regarding the most suitable treatment strategy, but their predictive ability is generally modest, and interscore variability is present. 47 Another hurdle is that bleeding risk is closely related to the stroke risk and some thromboembolic risk factors such as older age, uncontrolled hypertension, or history of stroke have also been identified as bleeding risk factors. 48 Thus, patients with high bleeding risk also have a high risk of stroke.
To minimize bleeding risk, while maintaining antithrombotic effect, 49 VKA therapy should be well managed, with a high TTR (>65%-70%), 50 and the lowest effective dose of aspirin should be chosen.
Regarding DOACs, the doses approved for stroke prevention should be used. Data on concomitant use of prasugrel or ticagrelor in patients taking OACs are scarce, and the risk of bleeding with either of these drugs may be excessive in combination with aspirin in anticoagulated patients. 31, 51, 52 Hence, clopidogrel is the preferred antiplatelet agent regarding PCI in patients with indications for OACs. 9,28,53 Importantly, new-generation drug-eluting stents and radial approach should be used to minimize bleeding risk, while proton pump inhibitors should be considered in all patients receiving TT to minimize gastrointestinal bleeding. 51 Concomitant use of nonsteroidal anti-inflammatory drugs should be avoided in patients with AF and ACS (Figure 2 ). 49 
| CHALLENGES IN COMBINED ANTITHROMBOTIC AND ANTIPLATELET THERAPY
One of the most challenging patients among AF population are those with AF and end-stage renal disease on hemodialysis. Severe chronic kidney disease (CKD) elevates the risk of major and intracranial bleeding, and this risk may be greater by the use of OAC or/and antiplatelet therapy. The evidence for antithrombotic therapy declines with the renal function. 54 There are no randomized trials dedicated to OACs in patients undergoing hemodialysis. Of note, there are currently 3 Apixaban Versus Warfarin in Atrial Fibrillation) trial, comparing apixaban 5 mg twice daily to warfarin. In one systematic review and meta-analysis 56 of 14 observational studies, the use of warfarin in patients with AF on hemodialysis was not associated with ischemic stroke or ICH. The use of warfarin in the above-mentioned population of patients was not associated with a clear benefit or harm.
In individuals with CKD who start an OAC, concomitant antiplatelet therapy including low-dose aspirin may substantially make bleeding risk higher and should be used judiciously. In dialysis-dependent patients, individualized decision making may be appropriate.
| FUTURE DIRECTIONS
Many questions regarding optimal combination(s) of antiplatelet and antithrombotic therapy in patients with AF and ACS or elective PCI remain unanswered, including optimal timing of aspirin cessation and adequate P2Y 12 inhibitor(s) to be used concomitantly with OACs. 57 The role of aspirin instead of a P2Y 12 
| ISTH 2019 MELBOURNE REPORT
At the ISTH Congress in Melbourne, there was much focus on AF risk assessment and aspects of its management.
For example, Osman 61 reported that machine learning algorithms had a good performance in predicting stroke outcomes (among others, type of stroke, 1-year survival, and post-stroke depression). Abdulrehman et al 62 
